Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hidaka
Clinical trial register · Japan

Clinical Trials in Hidaka, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC6 Daiichi Sankyo4 Eli Lilly and Company4 Genmab3 Janssen Research & Development, LLC3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Hidaka

39 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Pfizer
Phase 3
600
Sapporo, Akashi, Hidaka, Koto-ku, Niigata
2026-10-09
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Nagoya, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Hidaka, Sunto-gun,
2026-02-16
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Pfizer
Phase 3
800
Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku
2025-12-11
Recruiting
AbbVie
Phase 1
285
Kashiwa-shi, Hidaka, Sunto-gun
2025-11-27
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
1,630
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya
2025-10-22
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Akita, Asahikawa, Fukuoka, Hidaka, Hiroshima, Kobe, Matsuyama, Nagoya
2025-09-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Nagoya, Kashiwa, Sapporo, Kita-gun, Yokohama, Sendai, Sakai, Hidaka
2025-07-16
Recruiting
Eli Lilly and Company
Phase 3
700
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kōtō City
2025-03-27
Active, closed
Genmab
Phase 3
584
Nagoya, Kurume, Sapporo, Kawasaki, Sendai, Niigata, Okayama, Hidaka
2025-02-07
Recruiting
BioNTech SE
Phase 3
621
Ageo, Bunkyō City, Chūōku, Fukuoka, Hidaka, Himeji, Iwakuni, Kobe
2025-02-03
Active, closed
Daiichi Sankyo
Phase 2
335
Akashi, Chūōku, Fukuoka, Hidaka, Kashiwa, Kōtoku, Nagoya, Osaka
2025-01-06
Recruiting
NovoCure GmbH
Phase 3
734
Sakai, Hidaka, Bunkyo, Chuo-ku
2024-07-31
Recruiting
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Hidaka, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi, Saitama
2024-02-26
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
Recruiting
Eli Lilly and Company
Phase 3
1,264
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama
2023-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
19
Nagoya, Sapporo, Yokohama, Sendai, Matsumoto, Niigata, Hidaka, Izumo
2023-10-20
Recruiting
Takeda
Phase 3
240
Kurume-Shi, Kumamoto, Hidaka, Bunkyo-Ku, Setagaya-Ku
2023-05-16
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu, Hatsukaichi, Hidaka
2023-02-15
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Fukushima, Ōta, Sapporo, Akashi, Hidaka, Nagaizumi-chō, Koto, Shinjuku-ku
2022-12-07
Active, closed
Daiichi Sankyo
Phase 3
586
Akashi, Fukuoka, Hidaka, Hirakata, Iwakuni, Izumi, Kanazawa, Kōtoku
2022-07-08
Recruiting
Toray Industries, Inc
Phase 1/2
49
Nagoya, Fukuoka, Sapporo, Kumamoto, Matsumoto, Niigata, Hidaka, Nagaizumi-chō
2022-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka
2021-06-18
Active, closed
Daiichi Sankyo
Phase 3
605
Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku
2020-12-21
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bunkyō City, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kishiwada, Kobe
2020-10-13
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Recruiting
National Cancer Center Hospital East
Phase 3
110
Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa
2019-10-01
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Nagoya, Kashiwa-shi, Maebashi, Kasama-shi, Kyoto, Hidaka, Tokushima, Shibuya-ku
2019-01-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Nagoya, Kashiwa, Sapporo, Nishinomiya, Sagamihara, Kumamoto, Hidaka, Kitaadachi-gun
2018-12-27
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Nagoya, Kashiwa, Matsuyama, Sapporo, Kobe, Suita, Hidaka, Kitaadachi-gun
2018-06-21
Active, closed
Eisai Co., Ltd.
Phase 1
140
Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku
2017-08-18
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Sakai, Ageo, Hidaka, Koshigaya, Tokyo, Bunkyō-Ku, Minato-Ku, Yonago
2012-01
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/hidaka

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Hidaka.

How many clinical trials are recruiting in Hidaka?

26 of the 39 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hidaka), 39 studies
PhaseStudiesRecruitingShare
Phase 3261766.7%
Phase 25212.8%
Phase 1327.7%
Phase 1/2337.7%
Observational225.1%

Most active sponsors

Lead sponsors with the most studies (Hidaka)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC63
Daiichi Sankyo41
Eli Lilly and Company44
Genmab32
Janssen Research & Development, LLC31
BioNTech SE22
Medtronic22
Pfizer21
AbbVie11
ARCAGY/ GINECO GROUP11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.